Abstract: A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.

Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.

Abstract: Lacrimal implants and related methods providing secure, wedgable retention within a lacrimal punctum and associated canaliculus of an eye are disclosed. The lacrimal implants can comprise an implant body configured for at least partial insertion through the lacrimal punctum and into the canaliculus. The implant body can include first and second portions, and can extend from a proximal end of the first portion defining a longitudinal proximal axis to a distal end of the second portion defining a longitudinal distal axis. The implant body can be configured such that, when implanted using an integral dilator, an angled intersection exists between the proximal and distal axes. In this way, at least a portion of the implant body can be biased against at least a portion of the lacrimal canaliculus located at or more distal to a canalicular curvature, thereby retaining an implanted position of the lacrimal implant using anatomical structures.

Abstract: The present method involves the photodynamic treatment of acne vulgaris. The method involves the topical administration of a photosensitizer composition comprising hydrophobic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to acne-affected skin and subsequent exposure of that skin to energy of a wavelength of activating the photosensitizer.

Abstract: Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.

Abstract: Insertion and extraction tool, systems, and methods for use with lacrimal implants. An insertion tool is disclosed that includes a proximal end, a distal end, and a tool body therebetween. The distal end includes a mechanical coupling to receive a cartridge preloaded with a lacrimal implant, and a plunger configured to dispense the lacrimal implant from a preloaded cartridge.

Abstract: The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to affected skin and subsequent exposure of that skin to energy of a wavelength capable of activating the photosensitizer.

Abstract: The present invention relates to a photodynamic method of treating prostatic disorders such as BPH. The method comprises: administering a photosensitizer by direct injection to the prostate tissue of a subject afflicted with or suspected of being afflicted with a prostatic disorder; and irradiating the prostate tissue with energy at a wavelength appropriate to activate the photosensitizer, wherein a guidewire is utilized to position the injection device and the irradiation apparatus.

Abstract: The present invention relates to a photodynamic method of treating prostatic disorders such as BPH. The method comprises: (i) delivering photosensitizer directly into prostatic tissue of a patient suffering from or suspected of suffering from a prostatic disorder; and (ii) irradiating the prostatic tissue with a light at a wavelength appropriate to activate the photosensitizer.

Abstract: The present invention relates to the use of low-dose photodynamic therapy (PDT) to prevent, treat, inhibit or reduce restenosis in blood vessels. The present invention may be used in combination with any angioplastic procedure to prevent restenosis or to decrease the intima thickness, and thus luminal narrowing.